Identifying new markers for lung disease
Identification of Novel Markers of Human Lung Disease
This study is trying to find new markers in lung tissue from patients waiting for a lung transplant to help understand lung diseases better and develop new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ohio State University Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT02369575 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the progression and causes of interstitial lung diseases by analyzing lung tissue samples from patients on the lung transplant list. Participants will allow their discarded lung tissue to be used for research, enabling researchers to isolate specific cells and measure the cellular, molecular, and genetic mechanisms involved in lung disease. The goal is to uncover novel biomarkers that could lead to new treatments and therapeutics for advanced lung conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who are on the lung transplant list.
Not a fit: Patients who are HIV positive will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this research could lead to the development of innovative therapies for patients suffering from advanced lung diseases.
How similar studies have performed: While this approach is focused on identifying novel biomarkers, similar studies have shown promise in understanding lung diseases and developing targeted therapies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * any one on lung transplant list Exclusion Criteria: * HIV positive
Where this trial is running
Columbus, Ohio
- Davis Heart and Lung Research Institute — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Megan Ballinger — Ohio State University
- Study coordinator: Megan Ballinger
- Email: megan.ballinger@osumc.edu
- Phone: 614-292-6578
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.